about
Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responsesInhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation.Immune-based approaches for control of HIV infection and viral-induced immunopathogenesis.Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in miceNorovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.A novel tumour necrosis factor receptor mutation in a Finnish family with periodic fever syndrome.Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccineMultiple consecutive norovirus infections in the first 2 years of life.Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles.Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like ParticlesGenetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013.Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus.Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigens.GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model.Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.Norovirus-Specific Memory T Cell Responses in Adult Human Donors.Rotavirus vaccination and infection induce VP6-specific IgA responses.Simple and efficient ultrafiltration method for purification of rotavirus VP6 oligomeric proteins.Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.Assessment of Functional Norovirus Antibody Responses by Blocking Assay in Mice.Development and maturation of norovirus antibodies in childhood.Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display.Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children.High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children.Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays.Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography.Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype.A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.Analysis of the costimulatory requirements for generating human virus-specific in vitro T helper and effector responses.Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects.Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010.
P50
Q28347291-5E1F6CE2-1EFC-407A-9AEE-9C4031D79EA3Q33804258-277E22F7-6C3A-4B85-B90B-BA0DE1476E7AQ34040028-BD8EAD28-26CA-48D6-B9C4-AF01290F848AQ34291161-9C0FCBDD-E2B7-4B25-BA2E-8491A90FB5FBQ34907018-2450065C-5FDD-48D5-80FF-9742E1DE3550Q35624658-3D913AAE-86A1-40BA-B30C-7FEAF2D5A66DQ35656636-AB21ED65-6265-42CB-9C39-CD86C8686F1EQ35823352-9D242969-2FE6-4716-A97E-9C2A34A358CEQ35941247-1AD4A557-C79E-46DC-9B07-D056787C64F0Q36327158-DBEA5A1F-C3C3-4AD4-B0D3-E29166241518Q37135255-E6396EA3-7F6C-4D4D-AF5E-D0538693EEFBQ38341551-639B454E-1AB5-4297-A768-269933A6FB21Q38743049-56EF8257-415F-437E-819A-D45D73C327F5Q39190610-93FB2A09-6F68-4332-88AA-4508C9096182Q39442498-59658775-C390-4BB4-90A0-881443C5075DQ39538904-D64D56B9-12E0-4971-BDB9-5FE727F91669Q40069294-9921E945-35B0-4400-BFDE-A1CE3026D8CDQ40173137-05E85CF6-F20C-4350-8053-A84C88D568A2Q40243520-F044EF67-6BCA-480E-8DAE-218E757C225DQ40502202-9F23076C-253C-4FBE-8073-0D780AA8282EQ40608783-99BA79DF-A95D-4C9D-99FF-DEA5CC70749CQ40624553-E8362ACC-7236-4AB3-9C61-AA362D73A70EQ40691241-17303772-26F3-4835-87DB-F3B2C9255E7CQ40715789-1A2B31D6-1E82-4A33-8203-F989E61E7A36Q40847868-73690A37-DA1A-44A9-ABE6-B802900D0D11Q41254719-4D653427-0AAE-4BF6-9BC1-F7429ABD3CEFQ41412749-4602BC05-B28C-4A81-8EAD-4922A77A7660Q41590327-FB9B2D51-D478-484A-BFE2-D81480FC96DCQ41846635-8E0C5717-E279-4D53-8433-79C03591E233Q42209669-BEEEB2D4-72F6-4029-954B-C64D8540A16BQ42231266-B0AF1BB8-2130-4CD4-B75D-6AC633B388E8Q44197060-CB7EB525-BE5D-4BC4-BF8B-671FE7E8D13FQ44603123-F5A39BC4-706C-4D09-A7D2-D20828258DECQ45352453-CEE8030E-4076-4960-9A64-B45A775EE96FQ45362011-599DE3A3-5D45-41E9-A886-30C68EDEE7F7Q45421562-597CEA74-04A2-4CBA-BEA6-520C20A8A1A3Q45736079-C66F61D2-A6D7-4FD3-A79B-A94F3DF918F1Q45738342-5FF51B69-F087-423D-833D-CB20F40CFEB4Q47564996-24C5CDC8-2498-49C0-9529-891EF722A1E5Q51025702-43ADBCC9-0B6B-450F-B1CE-1377D981C592
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vesna Blazevic
@ast
Vesna Blazevic
@en
Vesna Blazevic
@es
Vesna Blazevic
@nl
Vesna Blazevic
@sl
type
label
Vesna Blazevic
@ast
Vesna Blazevic
@en
Vesna Blazevic
@es
Vesna Blazevic
@nl
Vesna Blazevic
@sl
prefLabel
Vesna Blazevic
@ast
Vesna Blazevic
@en
Vesna Blazevic
@es
Vesna Blazevic
@nl
Vesna Blazevic
@sl
P1053
Q-3183-2017
P106
P21
P2798
P31
P3829
P496
0000-0001-8201-6118